SCHEDULE: EcoR1 Capital Discloses 6.9% Stake in ORIC Pharma

EcoR1 Capital, LLC and its affiliates have disclosed a 6.9% beneficial ownership stake in ORIC Pharmaceuticals, Inc. common stock.

Summary

• EcoR1 Capital, LLC, along with its control person Oleg Nodelman, beneficially owns 6,728,116 shares of ORIC Pharmaceuticals, Inc. common stock, representing 6.9% of the class.
• EcoR1 Capital Fund Qualified, L.P., an affiliate, beneficially owns 6,283,426 shares, representing 6.5% of the class.
• The percentage of ownership is calculated based on 97,119,670 shares of Common Stock outstanding on July 29, 2025, as disclosed by the Issuer.
• All reported shares are held with shared voting and shared dispositive power by the respective reporting persons.
• The securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of ORIC Pharmaceuticals, Inc.

Sentiment

Score: 6

Explanation: The filing is a factual disclosure of ownership. The presence of a significant institutional investor like EcoR1 Capital can be interpreted as a positive signal of confidence in the company's prospects, though the filing itself does not contain operational or financial performance data.

Positives

• The disclosure of a significant stake by EcoR1 Capital, a notable investment firm specializing in healthcare, may signal institutional confidence in ORIC Pharmaceuticals, Inc.

Future Outlook

NA

Industry Context

This filing indicates continued institutional investor interest in the biotechnology sector, specifically in companies like ORIC Pharmaceuticals, Inc., which are typically focused on drug discovery and development.

Stakeholder Impact

• Shareholders: Increased transparency regarding significant institutional ownership.

Key Dates

Keywords

ORIC Pharmaceuticals, EcoR1 Capital, Oleg Nodelman, Beneficial Ownership, Schedule 13G, Common Stock, Institutional Investor, Biotechnology